What biomarker tests should I ask for with melanoma

According to the NCCN Guidelines for Melanoma, there are several important biomarker tests that should be considered. Here are the key recommendations:

According to the NCCN Guidelines:

1. BRAF mutation testing is one of the most important biomarker tests for melanoma patients, as BRAF mutations are commonly found in melanomas and can affect treatment options. The guidelines specifically mention that "BRAF mutations can cause normal cells to become cancerous" and are "most commonly found in melanomas."

2. The NCCN Guidelines recommend biomarker testing particularly for:

• Patients with advanced melanoma (stage III or IV)
• Cases where targeted therapy might be considered
• Situations where clinical trial eligibility needs to be determined

The American Society of Clinical Oncology (ASCO) guidelines also support molecular testing, particularly:

• BRAF mutation testing
• PD-L1 testing (which can help determine likelihood of response to immunotherapy)

Always remember that biomarker testing decisions should be made in consultation with your healthcare team, as they will consider your specific situation, including:

• Stage of disease
• Overall health status
• Potential treatment options
• Clinical trial opportunities

Please discuss with your healthcare provider which specific biomarker tests are most appropriate for your individual case, as testing recommendations can vary based on your specific situation and disease stage.